Publications by authors named "David Thacker"

Claim this Profile
C
CYP450 activity, drug interactions, and genetic polymorphisms: clinical relevance for the new selective cardiac myosin inhibitors.
Milind Y Desai, Veronique Michaud, David Thacker, Matthew Arwood, Pamela Dow

Expert Opin Drug Saf· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Pain Management in a CYP2D6 Poor Metabolizer: A Case Report for Oxycodone.
Deepa Pednekar, Joshua Russell, Chandni Bardolia, David Thacker, Nishita Shah Amin

Sr Care Pharm· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilizing Pharmacogenomics Results to Determine Opioid Appropriateness and Improve Pain Management in a Patient with Osteoarthritis.
Katie Pizzolato, David Thacker, Nicole Marie Del Toro-Pagán, Nishita S Amin, Abeer Hanna

Pharmgenomics Pers Med· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenomics and Drug-Induced Phenoconversion Informed Medication Safety Review in the Management of Pain Control and Quality of Life: A Case Report.
Selina Muhn, Nishita Shah Amin, Chandni Bardolia, Nicole Del Toro-Pagán, Katie Pizzolato, David Thacker

J Pers Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cannabis Dopaminergic Effects Induce Hallucinations in a Patient with Parkinson's Disease.
Katie Pizzolato, David Thacker, Nicole Del Toro-Pagán, Abeer Hanna, Jacques Turgeon

Medicina (Kaunas)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacist-Led Medication Evaluation Considering Pharmacogenomics and Drug-Induced Phenoconversion in the Treatment of Multiple Comorbidities: A Case Report.
Nicole Marie Del Toro-Pagán, Adriana Matos, David Thacker, Jacques Turgeon, Nishita Shah Amin

Medicina (Kaunas)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.
John J Lima, Cameron D Thomas, Julia Barbarino, Zeruesenay Desta, Sara L Van Driest, David L Thacker

Clin Pharmacol Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Brief Background on Cannabis: From Plant to Medical Indications.
Linda E Klumpers, David L Thacker

J AOAC Int· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity?
David L Thacker, Anil Modak, David A Flockhart, Zeruesenay Desta

J Breath Res· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity.
David L Thacker, Anil Modak, Phuong D Nguyen, David A Flockhart, Zeruesenay Desta

Chirality· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis